Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2500+0.1600 (+3.91%)
At close: 04:00PM EST
Advertisement
Sign in to post a message.
  • M
    Morgan
    Great presentation today. CEO crammed the whole pipeline update and company drug study developments into the short time allotment. Highlights were many.

    -Covid study still on track for readout this quarter. Found extremely high C5a levels in these patients and cited studies that confirmed that C5a activation is associated in the thrombosis involved with ARDS in Covid patients. He was very excited for the read out. If positive they will advance it for a roll out. It would take 30% overall improvement for a convincing result over placebo and said that no company to date has been successful in such a trial.

    -He spoke about new oral C5aR program and stated that it may be best in class over Avacopan (CCXI drug) with improved binding and he will be launching studies potentially to treat nephritis and peritonitis.

    -He updated the HS and PG and ANCA vasculitis studies and was excited about the Feb 3 HS update and spoke about how he has worked with the FDA to get the "bugs" out of the pivotal FDA trial that blindsided the SHINE study in 2019.

    -He spoke of the Squamous Cell Ca study and they are working in collaboration with Merck in a Vilo and Ketruda combo study for SCC and other possible collaborations.

    -He briefly mentioned several other iv anti-inflammatory compounds that are in phase 1 and 2 status.

    -He said that the company is financially set to further all of the above mentioned studies.
  • M
    Morgan
    The oral c5aR program, if successful could be a blockbuster drug. I am also hoping that it hints that Vilo is working in the Covid study, and I do not think at all that it represents a change in direction or emphasis for ongoing Vilo studies in HS, PG and ANCA vasculitis. Prior to the oral form, Vilo was a hospitalization setting drug. c5aR offers to take it into the outpatient setting to treat various inflammatory and autoimmune disorders. I am still long and strong and adding at these discounted levels and have not been dissuaded in the least by the lack of stock momentum given the biotech slaughter of the last 6 weeks.
  • O
    ORESTIS
    Last year we had the same pattern.
    Slow erosion followed by a sudden
    jump based on good news.
    The company still offers good value
    and has a strong balance sheet.
  • r
    rebolledo
    I am so tired of IFRX doing nothing all day. Can you move??? I have been reading http://alert-sounds.com/ for a month now and the stocks there actually go!
  • W
    WALLSTREET
    Just A REMINDER to you ALL.
    On 2019 IFRX traded at $52 level , when lately the NEWS wires are much Encouraging then in the past .
    With one MAJOR NEWS OUT , imho, you can see the STOCK PRICE @ $20 in a matter of weeks .
    Mark this post please .
    Bullish
  • L
    Lchaim54
    This stock is very hard to gauge despite any good news that should move this thru the 5.00 level
    Every time this stock has a good day it sells off after hours and vice versa
    Today they presented virtually at HC Wainwright Healthcare Conf
    Ther will be presenting as well at JP MORGAN HEALTHCARE CONFERENCE this Thurs Jan 13

    IRX closed at $3.88 last Friday
    closed +.39 at $4.27 today and
    +.12 at $4.39

    Market makers really play around with this one
    Bullish
  • M
    Max
    Love the almost 5% spread the MM's are putting inn here. Very telling! Once this stock starts to run, and I mean to really run on good news, the price will go absolutely ballistic.
  • L
    Lchaim54
    LOOKIN GOOD-$5.00 will send shorts to the hills
    Bullish
  • O
    ORESTIS
    The decline is on low volume.
    Lets see if we see a run up
    before the presentation
    on Jan 13.
  • j
    jim s
    sold @ 4.60 Monday I bought 1 share today @3.90 so won't forget this one will buy again
  • j
    jim s
    Sure glad I bought 30% more yesterday maybe this is the real rebound off to $10///$20 who knows staying long
    Bullish
  • .
    .
    With Phase III results pending on the Severe Covid study, I expect the Omicron variant news is about to push IFRX much higher.

    Omicron is widely being reported as a severe variant, which is why the World Health Organization designated Omicron a variant of concern. (Which is the WHO's highest alert level.)

    Many of the Covid-related stocks that ran up big in 2020 were previously small cap bios that had traded flat to down for years. The emergence of Covid, however, drove these stocks much higher as speculative plays and/or because these companies later provided actual solutions.

    IFRX market cap is currently around $225M, and the PPS is $5.00 The big money investment community could easily and quickly push IFRX far higher simply as a speculative play, and in anticipation of the Phase III Severe Covid study results.

    Recall, as recently as 2019 IFRX traded in the $40s. Yes, results from a prior study decimated IFRX and the stock has yet to recover.

    Regardless, the fact remains that IFRX did at one time trade far higher; and at a time when there wasn't a global pandemic and IFRX didn't have a potential Covid-related drug. (Moreover, IFRX has a number of other late stage study results on the horizon, which may very well also support a higher PPS.)

    A 4x price increase from here would place IFRX at $20 a share. And even at $20, the stock would be trading at less than half of its all-time high, and the company's total market cap would still be under $1B - a fraction of many other "Covid stocks."

    The upside far outweighs the downside on IFRX right now, and I expect we're soon going to look back, find IFRX trading far higher, and wonder why we didn't buy more at $5.00 when it was obvious we should have.

    IFRX @ $25+ by the end January 2022? I'm guessing it's going to happen. We'll see....
  • A
    Alex
    I suspect this company lack ethics. That's why stock price goes DOWN! If the phase 3 HS news was already known by the co in Sep Oct - why did they release it to investors ONLY NOW??? Scam?!...
  • j
    jim s
    can't help myself bought more @ $4.06
  • N
    Neil
    hang tough got to stay in it to win it resist giving him your shares because this is all margin call selling across the board 👁️
  • G
    GregR
    It is amazing the late day manipulation that occurs to drive price down. I agree with post below, any good news and this starts a run back towards low $20's . too much in process right now and trending well. Even if you disregard the Covid drug, the others should drive a $20 plus valuation based on competitive biotech companies.
    Bullish
  • M
    Morgan
    What is interesting is the observations by IFRX coming out of the Hidradenitis and the Pyoderma studies. They have shown that Vilo, through the down regulation of activated T cells via c5a inhibition, prevented the activated T cells from leaving the vasculature through electron microscope analysis. It is this very process of T cell activation that is an important contributor to the pathogenesis of end organ involvement in Covid ICU hospitalized patients. Today is a day where Covid is in the news for a possible more resistant resurgence and we are on the cusp of our readout data of our German government sponsored trial involving intubated Covid patients in about two months' time. PFE and MRK drugs do not deal with this aspect of the immune cascade in late stage Covid.
  • O
    ORESTIS
    Nice entry point.
  • M
    Morgan
    I looked over the vasculitis results to date and on the surface I agree that the look underwhelming, but they have to be considered in the context of ChemoCentryx's results. To start I am a clinician and am not much of an expert in this area of study read outs. I do have experience investing in CCXI and they had a bear of a time getting FDA approval and recieved a CRL upon submission of their ANCA vasculitis data and had to submit additional data and wait four months for final approval. The issues that came up are identical to those seen in these study results. In short ANCA is a terrible multisystem autoimmune vasculitis and these patients are on serious doses of steroids and even chemo (Immuran) on a chronic basis and there is a high mortality from drug side effects as well as the disease itself. So it is really hard to withdraw steroids cold turkey, but in part this study did this with results comparable or even better than the CCXI study. (you will have to go to that website to read the results and explore the issues that lead to the CRL for yourself--it can fill a book). So the study results showed that you can do combination therapy with Vilo and standard of care as well as vilo alone and the results were pretty much comparable BUT NOT BETTER than standard of care alone. This is the expected result and is really positive for FDA approval in the context of the CCXI study. The goal is to get these patients off steroids or reduce the use of steroids down the road while controlling the disease. The study is not meant to show a clearing of vasculitis. The sell off in IFRX in my mind is pure market profit taking after a huge run up. Also this stock is thinly traded and the Big Boys are trying to get shares out of weak hands and to me this is all computer trading algos trying to steal your shares over the last 2 days. With CCXI the manipulation was nuclear. In the hours before the approval announcement the stock plummeted from 22 to 12 in after hours and many panic sold only to wake up and find out the stock was approved and was trading as high as $37. SO BUCKLE UP. ANCA vasculitis is a rare disease but companies are willing to pay 200 k a year for monthly infusions and HS and PG are also rare diseases. But it is the expanded indications where the money will be. On the CCXI board analysts are putting strong buys on the stock with price targets of $100 plus or 9 B valuation. Our vasculitis results were somewhat better overall to those of CCXI as far as I remember but you should do your own DD. Pimple popper here not a scientist. All good in these studies though--no red flags.
  • M
    Morgan
    IFRX closed in Germany at 4.67 EU or 5.23$ today. Happy Thanksgiving and let's hope for a carry over tomorrow!
Advertisement
Advertisement